City

Beijing (1)

Condition

Myelosuppression Adult (2)

Chemotherapeutic Toxicity (1)

Chemotherapy-induced Neutropenia (1)

Febrile Neutropenia (1)

Gynecologic Cancer (1)

Small Cell Lung Cancer (1)

Overall Status

Approved for marketing (1)

Unknown status (1)

Sign in for free

Phase

phase 4 (1)

Sponsor

G1 Therapeutics, Inc. (1)

Lei Li (1)

Collaborator

Bionical Emas (1)

Intervention

long-acting g-csf (1)

short-acting g-csf (1)

trilaciclib (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Expanded Access (1)

Interventional (1)

Myelosuppression Adult

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Myelosuppression Adult, Chemotherapeutic Toxicity, Small Cell Lung Cancer Trial (Trilaciclib)

Approved for marketing

Myelosuppression Adult
+2 more

Trilaciclib

(no location specified)

Mar 17, 2021

Gynecologic Cancer, Myelosuppression Adult, Febrile Neutropenia Trial in Beijing (Long-acting G-CSF, Short-acting G-CSF)

Unknown status

Gynecologic Cancer
+3 more

Long-acting G-CSF
Short-acting G-CSF

Beijing, Beijing, China

Lei Li

Jan 3, 2019